Ignite Creation Date:
2024-05-06 @ 4:04 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04855045
Status:
UNKNOWN
Last Update Posted:
2022-03-25
First Post:
2021-04-13
Brief Title:
An Open-label Dose Escalation and Double-masked Randomized Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children 8 Years of Age With LCA10 Caused by Mutations in the CEP290 Gene
Sponsor:
ProQR Therapeutics
Organization:
ProQR Therapeutics
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Leber Congenital Amaurosis 10 |
| Blindness |
| Leber Congenital Amaurosis |
| Vision Disorders |
| Sensation Disorders |
| Neurologic Manifestations |
| Eye Diseases |
| Eye Disorders Congenital |
| Retinal Disease |
| Retinal Degeneration |
| Retinal Dystrophies |